Research

Hormonal

Exendin-4 (a GLP-1 receptor agonist) directly reduces hepatic triglyceride stores in human hepatocytes by activating PDK-1 and PKC-f signaling pathways, independent of insulin.

This research suggests that GLP-1 receptor agonists (like exendin-4) may help reduce fatty liver disease by directly acting on liver cells to lower fat storage, rather than just through insulin regulation. This mechanism is independent of insulin, making it potentially useful for patients with insulin resistance or type 2 diabetes who also suffer from non-alcoholic fatty liver disease (NAFLD).

ModerateSupportsMEDIUM confidence
exendin-4 has a direct effect on the reduction of hepatic steatosis in the absence of insulin... Treatment with exendin-4 quantitatively reduced triglyceride stores compared with control-treated cells.
Nitika Gupta et al. · Hepatology · 2010

Why this rating

High-quality mechanistic data (Western blots, siRNA knockdown, lipid assays) but limited to in vitro models (HepG2, Huh7, primary hepatocytes) without human clinical trials.

Source

Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway

Nitika Gupta et al. · Hepatology · 2010

DOI 10.1002/hep.23569

mechanism_onlyCited 513×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →